AMC.GB Crism Therapeutics Corp

TIDMAMC

RNS Number : 5693Z

Amur Minerals Corporation

25 January 2022

25 January 2022

AMUR MINERALS CORPORATION

("Amur" or the "Company")

(AIM: AMC)

Response to Press Speculation and Share Price Movement

Amur Minerals Corporation, a nickel-copper sulphide mineral exploration and resource development company which possesses a wholly owned nickel sulphide asset located in the far east of Russia, notes the recent share price movement and press speculation that a potentially interested party has valued the Company at an indicative price of up to GBP100 million. The Company confirms that it is in discussions with a potential purchaser to sell its wholly owned subsidiary, Irosta Trading Limited, for approximately the indicated price. Irostra Trading Limited owns the Kun-Manie Project.

Such a disposal would constitute a fundamental change of business under AIM Rule 15 and therefore be subject to shareholder approval. There can be no certainty that any agreement will be reached in respect of the proposed disposal, nor as to the terms of the proposed disposal. A further announcement will be made in due course.

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Enquiries:

 
       Company                Nomad and Broker          Public Relations 
  Amur Minerals Corp.    S.P. Angel Corporate Finance      Blytheweigh 
                                     LLP 
   Robin Young CEO            Richard Morrison             Megan Ray 
                                  Adam Cowl                Tim Blythe 
                                                        +44 (0) 20 7138 
    +7(4212)755615           +44(0)20 3470 0470               3203 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

SPCPPUBGGUPPGGA

(END) Dow Jones Newswires

January 25, 2022 06:21 ET (11:21 GMT)

Crism Therapeutics (AQSE:AMC.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Crism Therapeutics (AQSE:AMC.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024